<?xml version="1.0" encoding="UTF-8"?><REUTERS CGISPLIT="TRAINING-SET" LEWISSPLIT="TRAIN" NEWID="1833" OLDID="18250" TOPICS="NO">
<DATE> 4-MAR-1987 17:07:06.01</DATE>
<TOPICS/>
<PLACES><D>usa</D></PLACES>
<PEOPLE/>
<ORGS/>
<EXCHANGES/>
<COMPANIES/>
<UNKNOWN> 
   F
   f0878 reute
r f BC-HUNTERDON-&lt;HUNT&gt;-SETS   03-04 0105</UNKNOWN>
<TEXT> 
<TITLE>HUNTERDON &lt;HUNT&gt; SETS DENTAL VENTURE</TITLE>
<DATELINE>    YARDLEY, Penn., March 4 - </DATELINE><BODY>Hunterdon Pharmaceuticals Inc
said it formed a joint venture with &lt;Chesapeake Biological
Laboratories&gt; and &lt;E.B. Michaels Research Associates&gt; to
develop C31G, a substance that may be useful in the treatment
or prevention of plaque.
    The substance, tested in pre-clinical trials at the
University of Pennsylvania, also has other uses as an
anti-fungal or anti-bacterial agent, the company said.
    It said Chesapeake Biological, a private company, owns 55
pct of the venture, E.B. Michaels 10 pct, while it holds the
remaining interest, and the patent for C31G.
 Reuter
 </BODY></TEXT>
</REUTERS>